Antimicrobial resistance among enteric pathogens

Advances in Experimental Medicine and Biology

Volumn 609, Issue , 2008, Pages 154-163

  Pickering, Larry K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; KANAMYCIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE;

AEROMONADACEAE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CAMPYLOBACTER COLI; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CONFERENCE PAPER; ENTEROINVASIVE ESCHERICHIA COLI; GASTROENTERITIS; HEMORRHAGIC COLITIS; HUMAN; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SALMONELLA; SALMONELLOSIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA; SHIGELLOSIS; TREATMENT INDICATION; VIBRIO CHOLERAE; YERSINIA ENTEROCOLITICA; CAMPYLOBACTER; CHILD; DIARRHEA; DRUG EFFECT; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; ENTEROPATHY; GRAM NEGATIVE INFECTION; MICROBIOLOGY; PATHOGENICITY; PRESCHOOL CHILD; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CHILD; CHILD, PRESCHOOL; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INTESTINAL DISEASES;

EID: 39149090363     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73960-1_12     Document Type: Conference Paper

References (52)

1. Aleksic S, Katz A, and Aleksic V, et al. (1993). Antibiotic resistance of Shigella strains isolated in the Federal Republic of Germany 1989-1990. Zentralbl Bakteriol, 279:484-493.
2. American Academy of Pediatrics. (2006). Shigella infections. In Pickering LK, Baker CJ, Long SS, and McMillan JA (eds.), Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. American Academy of Pediatrics, Elk Grove Village, IL, pp. 589-591.
3. Angulo FJ, Baker NL, and Olsen S. (2004). Antimicrobial use in agriculture - controlling the transfer of antimicrobial resistance in humans. Semin Pediatr Infect Dis, 2:78-85.
4. Bennish ML, Wasif AK, and Begum M, et al. (2006). Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae Type 1 infection in Bangladesh. CID, 42:356-62.
5. Bhutta ZA, Khan LA, and Shadmani M. (2000). Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother, 44:450-452.
6. Centers for Disease Control and Prevention. (2006). National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): 2003 Human Isolates Final Report. US Department of Health and Human Services, Atlanta, GA.
7. Cheasty T, Skinner JA, and Rowe B, et al. (1998). Increasing incidence of antibiotic resistance in shigellas from humans in England and Wales: recommendations for therapy. Microb Drug Resist, 4:57-60.
8. Coker AO and Adefeso AO. (1994). The changing patterns of Campylobacter jejuni/coli in Lagos, Nigeria after ten years. East Afr Med J, 71:437-440.
9. Eng JV, Marcus R, and Hadler JL, et al. (2003). Consumer attitudes and use of antibiotics. Emerg Infect Dis, 9:1128-1135.
10. Engberg J, Aarestrup FM, and Taylor DE, et al. (2001). Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis, 7:24-34.
11. Feierl G. Wagner U, and Sixl B, et al. (2001). Epidemiology of Campylobacteriosis and development of resistance in Styria, Austria [Abstract B-15]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. lnt J Med Microbiol, 291(Suppl 31):9.
12. Gallay A, Prouzet-Mauléon VP, and Kemph I, et al. (2007). Campylobacter antimicrobial drug resistance among humans, broiler chickens and pigs, France. Emerg Infect Dis, 13:259-266.
13. Gaudreau C and Gilbert H. (1998). Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob Agents Chemother, 42:2106-2108.
14. Gaudreau C and Gilbert H. (2003). Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob Agents Chemother, 47:2027-2029.
15. Gaudreau C and Michaud S. (2003). Cluster of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Quebec, Canada. Clin Infect Dis, 37:131-136.
16. Griffin PM, Tauxe RV, and Redd SC, et al. (1989). Emergence of highly trimethoprim-sulfameth- oxazole-resistant Shigella in a native American population: an epidemiologic study. Am J Epidemiol, 129:1042-1051.
17. Guerrant RL, Gilder TV, and Steiner TS, et al. (2001). Practice guidelines for the management of infectious diarrhea. Clin Infect Dis, 32:331-350.
18. Gupta A, Nelson JM, and Barrett TJ, et al. (2004). Antimicrobial resistance among Campylobacter strains, United States, 1997-2001. Emerg Infect Dis, 10:1102-1109.
19. Hakanen A, Jousimies-Somer H, and Siitonen A, et al. (2003). Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis, 9:267-270.
20. Harnett N. (1992). High level resistance to trimethoprim, cotrimoxazole and other antimicrobial agents among clinical isolates of Shigella species in Ontario, Canada - an update. Epidemiol Infect, 109:463-472.
21. Helms M, Vastrup P, and Gerner-Smidt P, et al. (2002). Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis, 8:490-495.
22. Helms M, Simonsen J, and Olsen KE, et al. (2005). Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J. Infect Dis, 191:1050-1055.
23. Hoge CW, Gambel JM, and Srijan A, et al. (1998). Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis, 26:341-345.
24. Jain SK, Gupta A, and Glanz B, et al. (2005). Antimicrobial-resistant Shigella sonnei. Limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility. Pediatr Infect Dis J, 24:494-497.
25. Johnson JR, Kuskowski MA, and Menard M, et al. (2006). Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status. J. Infect Dis, 194:194-198.
26. King CK, Glass R, and Bresee JS, et al. (2003). The management of acute gastroenteritis in children: oral rehydration, maintenance, and nutrition therapy: 2003 CDC guidelines. MMWR, 52(RR-16):1-16.
27. Krausse R and Ullmann U. (2003). In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother, 47:2946-2950.
28. Li, CC, Chiu CN, and Wu JL, et al. (1998). Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J. Infect Dis., 30:39-42.
29. Magee JT, Pritchard EL, and Fitzgerald KA, et al. (1999). Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-1998. BMJ, 319:1239-1240.
30. Melby KK and Mannsäker T. (2001). Antibiotic sensitivity pattern of Campylobacter spp recovered over a ten year period from patients residing in Oslo Area. [Abstract B-17]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol, 291(Suppl 31):9.
31. Molbak K, Gerner-Smidt P, and Wegener HC. (2002). Increasing quinolone resistance in Salmonella enterica serotype enteritidis. Emerg Infect Dis, 8:514-515.
32. Murray BE. (1989). Problems and mechanisms of antimicrobial resistance. Infect Dis Clin North Am, 3:423-439.
33. Nachamkin I, Ung H, and Li M. (2001). Fluoroquinolone resistant Campylobacter jejuni in Philadelphia, 1982-2000. [Abstract B-06]. In Hacker J (ed.), Abstracts of Scientific Presentations of the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, Sept 1-5, 2001. Int J Med Microbiol, 291(Suppl 31):6.
34. Nelson JM, Smith KE, and Vugie DJ, et al. (2004). Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J. Infect Dis, 190:1150-1157.
35. Ohara T, Kojio S, and Taneike I, et al. (2002). Effects of azithromycin on Shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother, 46:3478-3483.
36. Replogle ML, Fleming DW, and Cieslak PR. (2000). Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis, 30:515-519.
37. Saenz Y, Zarazaga M, and Lantero M, et al. (2000). Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob Agents Chemother, 44:267-271.
38. Safdar N, Said A, and Gangnon Re, et al. (2002). Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli 1057:H7 enteritis. A meta-analysis. JAMA, 288:996-1000.
39. Sanchez C, Garcia-Restoy E, and Garau J, et al. (1993). Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis, 168:1304-1307.
40. Sanders JW, Isenbarger DW, and Walz SE, et al. (2002). An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg, 67:533-538.
41. Sirinavin S and Garner P. (2000). Antibiotics for treating Salmonella gut infections. Cochrane Database Syst Rev, (2) CD001167.
42. Smith KE, Besser JM, and Hedberg CW, et al. (1999). Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med, 340:1525-1532.
43. Stevenson JE, Gay K, and Barrett TJ, et al. (2007). Increase in nalidixic acid resistance among non-typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother, 51:195-97.
44. Talsma E, Goettsch WG, and Nieste HL, et al. (1999). Resistance in Campylobacter species: increased resistance to fluoroquinolones and seasonal variation. Clin Infect Dis, 29:845-848.
45. Taylor DE and Chang N. (1991). In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Antimicrob Agents Chemother, 35:1917-1918.
46. Threlfall EJ and Ward LR. (2001). Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis, 7:448-450.
47. Vahaboglu H, Fuzi M, and Cetin S, et al. (2001). Characterization of extended-spectrum beta-lactamase (TEM-52)-producing strains of Salmonella enterica serovar typhimurium with diverse resistance phenotypes. J Clin Microbiol, 39:791-793.
48. van Duijkeren E, Wannet WJ, and Houwers DJ, et al. (2003). Antimicrobial susceptibilities of Salmonella strains isolated from humans, cattle, pigs, and chickens in the Netherlands from 1984 to 2001. J Clin Microbiol, 41:3574-3578.
49. Varma J, Molbak K, and Barrett TJ. (2005). Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis, 191:554-561.
50. Villa L, Mammina C, and Miriagou V, et al. (2002). Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy. J Clin Microbiol, 40:2662-2665.
51. Wedel S, Bender J, and Leano F, et al. (2005). Antimicrobial-drug susceptibility of human and animal Salmonella typhimurium, Minnesota, 1997-2003. Emerg Infect Dis, 11:1899-1906.
52. World Health Organization. (1999). Containing Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland, February 4-5.